Horizon Therapeutics Public (HZNP) Dips -0.4% on Lower-Than-Average Volume

By Chris Stiles • Friday, July 21 11:30 • Permanent Link

Horizon Therapeutics Public logged a -0.4% change during today's morning session, and is now trading at a price of $101.53 per share. The S&P 500 index moved 0.0%. HZNP's trading volume is 1,014,707 compared to the stock's average volume of 2,218,891.

Horizon Therapeutics Public trades -12.85% away from its average analyst target price of $116.5 per share. The 7 analysts following the stock have set target prices ranging from $116.5 to $116.5, and on average have given Horizon Therapeutics Public a rating of hold.

If you are considering an investment in HZNP, you'll want to know the following:

Horizon Therapeutics Public's current price is 209.9% above its Graham number of $32.76, which implies that at its current valuation it does not offer a margin of safety
Based on its trailing earnings per share of 1.58, Horizon Therapeutics Public has a trailing 12 month Price to Earnings (P/E) ratio of 64.3 while the S&P 500 average is 15.97
HZNP has a forward P/E ratio of 15.0 based on its forward 12 month price to earnings (EPS) of $6.76 per share
The company has a price to earnings growth (PEG) ratio of 3.98 — a number near or below 1 signifying that Horizon Therapeutics Public is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 4.55 compared to its sector average of 4.16
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.
Based in Dublin, the company has 2,145 full time employees and a market cap of $23.24 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.